As generic alternatives to Venofer^® (iron sucrose) and Injectafer^® (ferric carboxymaltose) enter the market, American Regent recognizes the importance of coverage policies that support both appropriate patient access and responsible healthcare spending.

American Regent is committed to maintaining competitive pricing and price parity, where appropriate, with generic entrants for Venofer and Injectafer.

As coverage policies are reviewed, we encourage health plans to evaluate current product economics rather than product designation alone. When branded and generic products offer comparable economic value, we respectfully ask that you provide:

We also ask you to look at supply continuity. IV iron therapies are widely used across inpatient and outpatient settings. Coverage policies that concentrate utilization among a limited number of manufacturers may reduce flexibility if a supplier experiences an unexpected disruption or has capacity constraints. Maintaining access to multiple manufacturers, particularly when economics are comparable, can help support supply resilience, provider flexibility, and uninterrupted patient care.

A coverage approach grounded in actual market economics can support cost-management objectives while preserving provider choice, maintaining patient access, and minimizing unnecessary administrative burden.

American Regent welcomes the opportunity to discuss current market conditions, product economics, and supply considerations as generic competition continues to evolve. When the economics are comparable, we believe patient access should be comparable as well.

All payer-related questions should be sent to corpcommunications@americanregent.com and include Payer Coverage in the subject line.

American Regent remains committed to supporting patient access, provider choice, supply reliability, and responsible healthcare spending.